NanHua Bio-medicine 南华生物
5 significant filings since 31 May 2026: 2 on regulatory inquiry, 1 on earnings pre-announcement and 1 on delisting warning lifted, and 1 other kind. The latest, on 10 Jul 2026: 2026-037 南华生物2026年半年度业绩预告的公告. On 10 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 220.54% to 277.94% from the same period a year earlier.
自 31 May 2026 起有 5 份重大公告：regulatory inquiry 2 份、earnings pre-announcement 1 份、delisting warning lifted 1 份，另有 1 类。最新一份（10 Jul 2026）：2026-037 南华生物2026年半年度业绩预告的公告。10 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 220.54% 至 277.94%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥45亿 | ¥74亿 | 11th lowest of 54 · 54 家中第 11 低 | |
| Trailing P/E 市盈率 | 118.3x | 104.6x | 17th highest of 38 · 38 家中第 17 高 | |
| P/B 市净率 | 16.7x | 3.4x | 4th highest of 54 · 54 家中第 4 高 | |
| Revenue Growth 营收增速 | 473.6% | 4.0% | Highest of 54 · 54 家中第 1 高 | |
| Profit Growth 净利增速 | 272.0% | 3.3% | 11th highest of 54 · 54 家中第 11 高 | |
| Gross Margin 毛利率 | 10.0% | 33.3% | 4th lowest of 54 · 54 家中第 4 低 | |
| Net Margin 净利率 | 0.3% | 5.8% | 17th lowest of 54 · 54 家中第 17 低 | |
| Return on Equity 净资产收益率 | 2.2% | 2.0% | 25th highest of 54 · 54 家中第 25 高 | |
| Debt to Assets 资产负债率 | 59.3% | 28.7% | 7th highest of 54 · 54 家中第 7 高 | |
| Grade Score 评级得分 | 40 | 52 | 18th lowest of 53 · 53 家中第 18 低 |
Statement figures are for the period to 30 Jun 2026, filed by 54 of 54 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，54 家同业中 54 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Wuxi Apptec 药明康德 | ¥4,929亿 | 22.7x | 5.8x | 38.9% | 38.5% | 13.2% | B |
| Pharmaron Beijing 康龙化成 | ¥799亿 | 46.7x | 4.9x | 17.9% | 9.4% | 4.6% | C |
| Aier Eye Hospital Group 爱尔眼科 | ¥736亿 | 28.9x | 3.2x | 3.8% | 12.9% | 6.0% | C |
| Asymchem Laboratories 凯莱英 | ¥645亿 | 62.3x | 3.6x | 13.1% | 14.3% | 2.9% | C |
| Biocytogen 百奥赛图 | ¥566亿 | 154.4x | 23.4x | 51.6% | 25.6% | 10.5% | B |
| Hangzhou Tigermed Consulting 泰格医药 | ¥489亿 | 535.2x | 2.5x | 14.1% | -5.0% | -2.0% | D |
| Joinn 昭衍新药 | ¥348亿 | 35.3x | 3.9x | 5.3% | 106.2% | 8.6% | B |
| Haoyuan Chemexpress 皓元医药 | ¥221亿 | 85.2x | 6.9x | 25.7% | 9.8% | 5.3% | C |
| BGI Genomics 华大基因 | ¥189亿 | — | 2.2x | 9.6% | 2.7% | 0.6% | D |
| Hitgen 成都先导 | ¥177亿 | 126.3x | 11.6x | 52.4% | 23.0% | 5.2% | B |
| Meinian Onehealth Healthcare Holdings 美年健康 | ¥175亿 | 54.1x | 2.2x | -6.4% | -5.0% | -2.2% | E |
| Topchoice Medical 通策医疗 | ¥149亿 | 24.2x | 3.6x | 4.1% | 32.8% | 9.5% | C |
| Gempharmatech 药康生物 | ¥147亿 | 80.7x | 6.5x | 22.6% | 24.1% | 4.8% | B |
| Medicilon 美迪西 | ¥145亿 | — | 7.2x | 40.9% | 6.8% | 2.6% | C |
| NanHua Bio-medicine 南华生物 | ¥45亿 | 118.3x | 16.7x | 473.6% | 0.3% | 2.2% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。